English | Español

Amgen Inc.
+ Regulatory
Robert Hadley | Apr 16, 2017

XGEVA pending approval for myeloma patients
Erianne Leatherman | Apr 9, 2017

Amgen’s BLINCYTO to receive priority review from FDA
Erianne Leatherman | Apr 7, 2017

Repatha shows no memory effects while lowering LDL levels, study finds
+ Technology/Innovation
Robert Hadley | Mar 28, 2017

European Commission approves Amgen's new anti-inflammatory drug
+ Technology/Innovation
Robert Hadley | Mar 22, 2017

Amgen’s Repatha may help patients with tough cases of high cholesterol
+ Technology/Innovation
Robert Hadley | Mar 17, 2017

Clinical trial shows immunotherapy can extend leukemia patients' life expectancy
+ Technology/Innovation
Mark Iandolo | Oct 24, 2016

Amgen announces study regarding its XGEVA product
+ Technology/Innovation
Amanda Rupp | Oct 3, 2016

Amgen to present new data concerning melanoma, metastatic colorectal cancer treatments

Trending
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Regulatory
M. R. Armstrong | Aug 4, 2026

Public Policy Solutions on 340B: 'The program has enriched big hospital execs'
+ Pharmaceuticals
Patient Daily | Aug 5, 2026

Bristol Myers Squibb and AstraZeneca reportedly in merger talks amid industry changes